Combining Targeted Therapies for Thoracic Cancers
Romidepsin is a new anticancer agent that belongs to a family of drugs called histone deacetylase inhibitors. These drugs can turn on genes in cancer cells that regulate cell growth and induce cell death (apoptosis). Unfortunately, the protein product of one of the genes activated by romidepsin, called p21, also interferes with the drug’s ability to induce apoptosis. Researchers think that combining romidepsin with other anticancer drugs may improve its ability to kill cancer cells.
This entry was posted on Tuesday, September 26th, 2006 at 2:28 pm and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.